Physician profile
Nihal Shah
NPI 1407829088
$6,285.78
in general payments reported to CMS, 2019-2025
32 companies · $1,307 in 2025
The $1,307 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $542 · 2021: $967 · 2022: $875 · 2023: $995 · 2024: $1,427 · 2025: $1,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,724 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,723.96 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,416.66 | 2021-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $1,294.88 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $530.72 | 2020-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $500.05 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $402.61 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alkermes, INC. | $230.00 | 2020-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $196.81 | 2020-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $190.70 | 2019-2024 | Invega, Invega Sustenna, Invega Trinza |
| Almatica Pharma LLC | $169.65 | 2021-2025 | Loreev Xr, Gralise |
| Takeda Pharmaceuticals U.S.A., INC. | $153.96 | 2019-2025 | Trintellix |
| Harmony Biosciences LLC | $148.82 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $144.38 | 2022-2024 | Quviviq |
| Noven Therapeutics, LLC | $133.51 | 2024-2025 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $99.53 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $66.21 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $64.37 | 2020-2021 | |
| Axsome Therapeutics, INC. | $62.61 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.23 | 2024-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $49.85 | 2020-2022 | |
| Indivior INC. | $45.73 | 2022-2024 | Sublocade |
| Tris Pharma INC | $42.22 | 2022-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $40.67 | 2022-2023 | Belsomra |
| E.R. Squibb & Sons, L.L.C. | $39.37 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $32.68 | 2020-2024 | Hetlioz, Fanapt |
| Bausch Health US, LLC | $32.07 | 2022-2025 | Aplenzin |
| Sage Therapeutics, LLC | $28.87 | 2025 | Zurzuvae |
| Eisai INC. | $23.71 | 2022 | |
| Shire North American Group INC | $19.71 | 2019 | |
| Avanir Pharmaceuticals, INC. | $18.83 | 2020 | |
| Neos Therapeutics, LP | $17.10 | 2022 | |
| Avion Pharmaceuticals | $14.90 | 2023 | Methylphenidate Hydrochloride |
| Allergan, INC. | $12.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nihal Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.